Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22423516 | 0.88 | GLP1R (0.54) | GLP1RCASP2FAAHNOD1NAAA | |
| SCHEMBL22478893 | 0.83 | GLP1R (0.68) | GLP1RCASP2FAAHNOD1NAAA | |
| SCHEMBL23544192 | 0.82 | GLP1R (0.53) | GLP1RCASP2FAAHNOD1NAAA | |
| SCHEMBL19057810 | 0.82 | GLP1R (0.57) | GLP1RCASP2FAAHNOD1NAAA | |
| SCHEMBL26803766 | 0.82 | GLP1R (0.57) | GLP1RCASP2FAAHNOD1NAAA | |
| SCHEMBL25067300 | 0.81 | FAAH (0.59) | GLP1RCASP2FAAHNAAADNM1 | |
| SCHEMBL23544193 | 0.81 | GLP1R (0.52) | GLP1REPHX2 | |
| SCHEMBL12122199 | 0.81 | GLP1R (0.70) | GLP1RNOD1EPHX2 | |
| SCHEMBL20991724 | 0.81 | GLP1R (0.69) | GLP1RNOD1EPHX2SLC6A5 | |
| SCHEMBL24592945 | 0.81 | GLP1R (0.69) | GLP1RNOD1EPHX2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3447067-B1 | GLP-1R/GCGR DUAL TARGET AGONIST POLYPEPTIDE FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASES | SHENZHEN TURIER BIOTECH CO LTD (CN) | 2021-06-23 | — | — | EP | disclosed |